HK1136283A1 - Compounds for the prevention and treatment of cardiovascular diseases - Google Patents

Compounds for the prevention and treatment of cardiovascular diseases

Info

Publication number
HK1136283A1
HK1136283A1 HK10102977.1A HK10102977A HK1136283A1 HK 1136283 A1 HK1136283 A1 HK 1136283A1 HK 10102977 A HK10102977 A HK 10102977A HK 1136283 A1 HK1136283 A1 HK 1136283A1
Authority
HK
Hong Kong
Prior art keywords
prevention
compounds
treatment
cardiovascular diseases
apolipoproteip
Prior art date
Application number
HK10102977.1A
Other languages
English (en)
Inventor
Henrik Hansen
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of HK1136283A1 publication Critical patent/HK1136283A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK10102977.1A 2007-02-01 2010-03-22 Compounds for the prevention and treatment of cardiovascular diseases HK1136283A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/670,238 US8053440B2 (en) 2007-02-01 2007-02-01 Compounds for the prevention and treatment of cardiovascular diseases
PCT/CA2007/000146 WO2008092231A1 (fr) 2007-02-01 2007-02-01 Composés destinés à la prévention et au traitement de maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
HK1136283A1 true HK1136283A1 (en) 2010-06-25

Family

ID=51894355

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10102977.1A HK1136283A1 (en) 2007-02-01 2010-03-22 Compounds for the prevention and treatment of cardiovascular diseases

Country Status (17)

Country Link
US (7) US8053440B2 (fr)
EP (1) EP2118074B1 (fr)
JP (1) JP5236664B2 (fr)
KR (1) KR101444489B1 (fr)
CN (1) CN101641339B (fr)
AU (1) AU2007345526B2 (fr)
CA (1) CA2676984C (fr)
CY (1) CY1115236T1 (fr)
DK (1) DK2118074T3 (fr)
ES (1) ES2454966T3 (fr)
HK (1) HK1136283A1 (fr)
MX (1) MX2009008099A (fr)
NZ (1) NZ579355A (fr)
PL (1) PL2118074T3 (fr)
PT (1) PT2118074E (fr)
SI (1) SI2118074T1 (fr)
WO (1) WO2008092231A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033480A1 (en) * 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
CN101365446B (zh) * 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
MX2009008099A (es) * 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
JP2011516610A (ja) * 2008-04-15 2011-05-26 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規な阻害剤
SI2346837T1 (sl) * 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
CN101628913B (zh) * 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CA2731926A1 (fr) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Naphtyridines a substitution 4-dimethylamino-phenyle, et leur utilisation en tant que medicaments
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
TW201033226A (en) 2008-11-28 2010-09-16 Chugai Pharmaceutical Co Ltd 1-(2h)-isoquinolone derivative
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CA3146333A1 (fr) * 2009-03-18 2010-09-23 Resverlogix Corp. Derives de la phenyl-quinazolin-4(3h)-one et de la phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one et leurs compositions utiles comme agents anti-inflammatoires
PL2421533T3 (pl) * 2009-04-22 2019-05-31 Resverlogix Corp Nowe środki przeciwzapalne
TW201121968A (en) * 2009-11-09 2011-07-01 Intermune Inc Novel inhibitors of hepatitis C virus replication
NZ600857A (en) 2010-01-29 2014-06-27 Boehringer Ingelheim Int Substituted naphthyridines and their use as syk kinase inhibitors
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
CA2804593C (fr) 2010-07-09 2015-11-24 Pfizer Limited Derives de biphenyloxybenzensulphonamide utiles en tant qu'inhibiteurs du canal sodique
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
EP2593427B1 (fr) 2010-07-12 2014-12-24 Pfizer Limited Dérivés de sulfonamides comme inhibiteurs du nav1.7 pour le traitement de la douleur
EP2593433B1 (fr) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendan
WO2012007868A2 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
CA2801032A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant
WO2012019093A1 (fr) * 2010-08-05 2012-02-09 Human Biomolecular Research Institute Composés synthétiques et procédés pour diminuer l'auto-administration de nicotine
EA024845B1 (ru) 2011-07-26 2016-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хинолины и их применение в качестве лекарственных средств
WO2013033269A1 (fr) 2011-08-29 2013-03-07 Coferon, Inc. Monomères bioorthogonaux capables de se dimériser et de cibler des bromodomaines et procédés d'utilisation correspondant
WO2013033270A2 (fr) 2011-08-29 2013-03-07 Coferon, Inc. Ligands de brodomaines capables de se dimériser dans une solution aqueuse, et procédés d'utilisation de ceux-ci
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US8710064B2 (en) * 2011-10-20 2014-04-29 China Medical University 2-aryl-4-quinazolinones and their pharmaceutical compositions
JP5992049B2 (ja) * 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
CN102516169B (zh) * 2011-12-31 2014-05-28 清华大学 制备多取代异喹啉及杂环并吡啶衍生物的方法
MX346147B (es) 2012-03-07 2017-03-09 Inst Of Cancer Research: Royal Cancer Hospital (The) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
JP6247294B2 (ja) * 2012-08-08 2017-12-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ （アザ−）イソキノリノン誘導体
AU2013333575B2 (en) * 2012-10-15 2015-07-16 Resverlogix Corp. Compounds useful in the synthesis of benzamide compounds
BR112015008171B1 (pt) * 2012-10-15 2021-01-19 Albemarle Corporation processos para a síntese de 2-amino-4,6-dimetoxibenzamida e de outros compostos de benzamida
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
JP6401773B2 (ja) 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
CA2915838C (fr) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Inhibiteurs de bromodomaine bicycliques
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
EA201690087A1 (ru) 2013-07-31 2016-08-31 Зенит Эпидженетикс Корп. Новые квиназолиноны как ингибиторы бромодомена
US20160346291A1 (en) * 2013-08-21 2016-12-01 Resverlogix Corp Compositions and therapeutic methods for accelerated plaque regression
MX2016002302A (es) * 2013-08-21 2016-06-15 Resverlogix Corp Composiciones y metodos terapeuticos para la regresion acelerada de placa.
CA2922469A1 (fr) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) Composes de 3-arylisoquinol-1-one 5-substituee et leur utilisation therapeutique
AU2014353006B2 (en) * 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
CA2966298A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Pyridinones substituees utilisees comme inhibiteurs de bromodomaines
WO2016087942A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Pyridines substituées comme inhibiteurs de bromodomaine
CA2966449A1 (fr) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Heterocycles substitues a titre d'inhibiteurs de bromodomaines
EP3233846A4 (fr) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibiteurs de bromodomaines
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
EP3268007B1 (fr) * 2015-03-13 2022-11-09 Resverlogix Corp. Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
WO2016196065A1 (fr) 2015-05-29 2016-12-08 Genentech, Inc. Procédés et compositions pour évaluer la réponse de cancers aux inhibiteurs bet
EP3348548A4 (fr) * 2015-09-07 2019-04-03 Zhejiang Huahai Pharmaceutical Co., Ltd Molécule de promédicament libérant de l'oxyde nitrique
CN109071562B (zh) 2016-02-15 2022-03-22 密执安大学评议会 作为bet溴结构域抑制剂的稠合1,4-氧氮杂䓬和相关类似物
US11192898B2 (en) 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
WO2017176958A1 (fr) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Intermédiaires monofonctionnels pour la dégradation d'une protéine cible dépendante du ligand
EP3442976B1 (fr) 2016-04-12 2022-07-20 The Regents of The University of Michigan Agents de dégradation de protéine bet
AU2017326175B2 (en) 2016-09-13 2022-01-27 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET protein degraders
JP6961684B2 (ja) 2016-09-13 2021-11-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔタンパク質分解物質としての縮合１，４−オキサゼピン
RU2016138751A (ru) * 2016-09-30 2018-04-02 Общество с ограниченной ответственностью "Диборнол Девелопмент" Средство для лечения сердечно-сосудистых заболеваний
JP6849804B2 (ja) * 2016-12-09 2021-03-31 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
EP3562483A4 (fr) 2016-12-20 2020-06-03 Oligomerix, Inc. Nouveaux analogues de benzofuranes, de benzothiophènes et d'indoles qui inhibent la formation d'oligomères tau et leur procédé d'utilisation
EP4252856A3 (fr) * 2016-12-20 2024-01-24 Oligomerix, Inc. Nouvelles quinazolinones inhibant la formation d'oligomères tau et leur procédé d'utilisation
US11046709B2 (en) 2017-02-03 2021-06-29 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET bromodomain inhibitors
CN108069954B (zh) * 2017-03-03 2018-11-23 上海华汇拓医药科技有限公司 含no供体的喹唑啉酮化合物
ES2681124B1 (es) 2017-03-08 2019-06-19 Fund Imdea Alimentacion Usos medicos de la apolipoproteina a y de activadores de la misma
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
WO2019055444A1 (fr) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan Agents de dégradation de protéine de bromodomaine bet avec des lieurs clivables
CN108484510B (zh) * 2018-05-18 2020-05-05 东南大学 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用
KR20210020889A (ko) 2018-06-13 2021-02-24 디블라이 아게 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도
WO2020131807A1 (fr) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leurs procédés d'utilisation
CN109776413A (zh) * 2019-01-29 2019-05-21 天津科技大学 一种具有降糖活性的异喹啉衍生物和应用
CN109897009B (zh) * 2019-03-15 2022-06-28 深圳晶泰科技有限公司 一种Apabetalone水合物晶型及其制备方法
CN109824608B (zh) * 2019-03-15 2022-06-21 深圳晶泰科技有限公司 一种Apabetalone晶型及其制备方法
JP7502811B2 (ja) * 2019-11-05 2024-06-19 レスバーロジックス コーポレイション Ｂｅｔブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体２阻害物質の組み合わせで主要な心血管有害事象（ｍａｃｅ）を処置および／または予防する方法
KR102420263B1 (ko) * 2019-11-26 2022-07-13 주식회사 베노바이오 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도
KR102420262B1 (ko) * 2019-11-26 2022-07-13 주식회사 베노바이오 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도
TW202140019A (zh) * 2020-01-08 2021-11-01 加拿大商瑞斯弗洛吉克斯公司 以bet溴結構域抑制劑及二肽基肽酶4抑制劑之組合治療及/或預防主要不良心血管事件（mace）的方法
CN115209894A (zh) 2020-03-06 2022-10-18 弗特克斯药品有限公司 治疗apol-1依赖性局灶节段性肾小球硬化的方法
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
JP2023539194A (ja) 2020-08-26 2023-09-13 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤およびこれを使用する方法
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CN115710202B (zh) * 2021-08-23 2024-05-03 江西同和药业股份有限公司 一种阿帕他酮关键中间体的制备方法及其应用
CN113754594A (zh) * 2021-09-16 2021-12-07 中国药科大学 喹唑啉酮类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
TW202337453A (zh) 2022-03-17 2023-10-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
WO2024171021A1 (fr) * 2023-02-13 2024-08-22 Aurobindo Pharma Ltd Procédé de préparation de belumosudil

Family Cites Families (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608A (en) * 1846-06-27 Netting-machine
US2065593A (en) * 1936-12-29 Water-soluble diazoimino com
US4448A (en) * 1846-04-04 Xjoel
FR472489A (fr) 1914-02-20 1914-12-08 Stas Motor Ges M B H Bague de garniture métallique pour pistons
US2065900A (en) * 1935-03-23 1936-12-29 Gen Aniline Works Inc Dihydroxystilbene-dicarboxylic acid and a process of preparing it
FR803619A (fr) 1935-03-23 1936-10-05 Ig Farbenindustrie Ag Acide du type dihydroxystilbène-dicarboxylique et son procédé de préparation
DE637259C (de) 1935-03-24 1936-10-27 I G Farbenindustrie Akt Ges Verfahren zur Darstellung einer Dioxystilbendicarbonsaeure
FR803201A (fr) 1935-07-08 1936-09-25 Ste Ind Chim Bale Préparation d'acides sulfoniques
US2071329A (en) * 1935-08-22 1937-02-23 Solvay Process Co Method of recovering phthalic anhydride
DE652772C (de) 1935-11-07 1937-11-08 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von N-Dihydroazinen der Anthrachinonreihe
GB728767A (en) 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
BE633049A (fr) 1962-06-06
US3251837A (en) * 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
GB1179019A (en) 1967-05-23 1970-01-28 Produits Chimique Soc Et Polynicotinic Esters of Flavonoids
FR6928M (fr) 1967-11-24 1969-05-05
US3600394A (en) * 1968-05-17 1971-08-17 Searle & Co 2-aminoalkyl-3-arylisocarbostyrils
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3862186A (en) 1972-12-15 1975-01-21 Bristol Myers Co Process for the production of cephalexin monohydrate
FR2244493A1 (en) 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE2349024A1 (de) * 1973-09-26 1975-04-10 Schering Ag 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione
IT1050750B (it) 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
GB1532682A (en) 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
US5098903A (en) 1980-03-07 1992-03-24 Board Of Regents Of The University Of Oklahoma Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) * 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) * 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
EP0182213B1 (fr) 1984-11-08 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Dérivés de carbapénème et leur préparatIon
DE3515882A1 (de) 1985-05-03 1986-11-06 Dr. Karl Thomae Gmbh, 7950 Biberach Arzneimittel, enthaltend pyridinone mit antithrombotischen wirkungen und verfahren zu ihrer herstellung
DE3532279A1 (de) 1985-09-11 1987-03-12 Bayer Ag 1,4-benzoxathiin-derivate
ES2058061T3 (es) 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
DE3601417A1 (de) 1986-01-20 1987-07-23 Nattermann A & Cie 2'-alkyl-(alkenyl-) substituierte quercetine
US4663345A (en) 1986-04-17 1987-05-05 American Home Products Corporation Etodolac for treatment of gout
EP0258190B1 (fr) 1986-08-29 1991-11-27 Ciba-Geigy Ag Procédé pour la fabrication d'éthers et thioéthers aromatiques
DE3784147T2 (de) 1986-11-24 1993-06-03 Fujisawa Pharmaceutical Co 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeure-derivate.
JPH07118241B2 (ja) 1987-10-21 1995-12-18 松下電器産業株式会社 器具の蓋開閉装置
GB8804058D0 (en) 1988-02-22 1988-03-23 Fujisawa Pharmaceutical Co 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds
US4925838A (en) 1988-03-18 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
US4963544A (en) 1988-05-23 1990-10-16 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
GB8926981D0 (en) 1988-12-23 1990-01-17 Ici Plc Heterocyclic derivatives
JPH0741442Y2 (ja) 1989-01-31 1995-09-27 シャープ株式会社 生体用電極保持体
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
FR2649612A1 (fr) 1989-07-17 1991-01-18 Rhone Poulenc Sante Medicaments a base de derives de 1h-benzoxadiazine-4,1,2 nouveaux derives et leurs procedes de preparation
IE64358B1 (en) 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
US5332832A (en) 1989-07-26 1994-07-26 Procter & Gamble Pharmaceuticals, Inc. Nitrofurantoin crystals
GB9018134D0 (en) 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
CA2224047A1 (fr) * 1990-06-05 1991-12-06 Toray Industries, Inc. Derives indole
JP2999579B2 (ja) * 1990-07-18 2000-01-17 武田薬品工業株式会社 Ｄｎａおよびその用途
IE913866A1 (en) 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
GB9025832D0 (en) 1990-11-28 1991-01-09 Ashwell Geoffrey J Novel films for nonlinear optical applications
US5126351A (en) * 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
CA2085136C (fr) 1991-04-10 1997-03-18 Ernest Kun Methode d'inhibition de la replication retrovirale
DK0584222T3 (da) * 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5124337A (en) * 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
FR2689127B1 (fr) 1992-03-31 1994-05-06 Adir Cie Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
DE4215588A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Biphenylmethyl-substituierte Pyridone
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
JPH0680656A (ja) 1992-09-03 1994-03-22 Mitsui Petrochem Ind Ltd 光学活性エポキシドの製造方法
AU5850894A (en) 1992-12-23 1994-07-19 Procept, Inc. Novel agents for inhibition of hiv infectivity and use therefor
JPH0741442A (ja) 1993-05-21 1995-02-10 Sumitomo Chem Co Ltd アセチレンアルコール誘導体およびその製造法
JPH0761942A (ja) 1993-06-17 1995-03-07 Sumitomo Chem Co Ltd フェノール誘導体およびその製造法
JPH0725761A (ja) 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
US5756763A (en) * 1993-07-23 1998-05-26 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Pyrrolidine derivatives
US5707547A (en) 1993-08-03 1998-01-13 Sumitomo Chemical Company, Limited Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition
JPH07118241A (ja) 1993-09-01 1995-05-09 Sumitomo Chem Co Ltd フェノール誘導体およびその製造法
JPH07179380A (ja) 1993-12-22 1995-07-18 Sumitomo Chem Co Ltd アルコール誘導体およびその製造法
JPH07233109A (ja) 1994-02-24 1995-09-05 Sumitomo Chem Co Ltd 光学活性なアルコール誘導体およびその製造法
CA2184101C (fr) * 1994-02-25 2005-11-22 Susumu Nakagawa Derive de carbapendem
ATE202567T1 (de) * 1994-03-08 2001-07-15 Otsuka Pharma Co Ltd Phosphorsäurediester-derivate
JPH07247289A (ja) 1994-03-11 1995-09-26 Mitsui Petrochem Ind Ltd クロメンオキシド類の製造方法
FR2718329B1 (fr) * 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US6048903A (en) * 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US6168776B1 (en) * 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
JP3702493B2 (ja) 1994-08-12 2005-10-05 大正製薬株式会社 キナゾリン−４（３ｈ）−オン誘導体
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
CN1085666C (zh) 1994-11-14 2002-05-29 沃尼尔·朗伯公司 用于抑制蛋白质酪氨酸激酶介导的细胞增殖的6－芳基吡啶并[2,3－d]嘧啶和1,5－二氮杂萘
US5446071A (en) * 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
JP4140981B2 (ja) * 1994-12-26 2008-08-27 東菱薬品工業株式会社 再狭窄症及び動脈硬化症治療薬
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
DE69622472T2 (de) 1995-06-07 2003-02-06 Eli Lilly And Co., Indianapolis Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
WO1997008153A1 (fr) * 1995-08-30 1997-03-06 Otsuka Pharmaceutical Factory, Inc. Procede de production de derives de quinazolin-4-one
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
WO1997010221A1 (fr) 1995-09-15 1997-03-20 Torrey Pines Institute For Molecular Studies Synthese de banques de quinazolinones
AU706262B2 (en) 1995-10-23 1999-06-10 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
RU2135494C1 (ru) 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5763608A (en) 1996-02-05 1998-06-09 Hoechst Celanese Corporation Process for preparing pyrimidine derivatives
WO1997028118A1 (fr) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Procede de preparation d'acides anthreniliques
US5739330A (en) 1996-02-05 1998-04-14 Hoechst Celanese Corporation Process for preparing quinazolones
ES2161442T3 (es) 1996-02-12 2001-12-01 Univ Rutgers Analogos de coralina como inhibidores de topoisomerasa.
PL330814A1 (en) 1996-06-20 1999-06-07 Regents Board Of Compounds for and methods of delivering pharmaceutical preparations and their application
US5854264A (en) * 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100213895B1 (ko) * 1996-10-14 1999-08-02 박원훈 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물
DE19651099A1 (de) 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6613722B1 (en) 1997-03-07 2003-09-02 Exxon Chemical Patents Inc. Lubricating composition
JPH10287678A (ja) 1997-04-11 1998-10-27 Kyowa Hakko Kogyo Co Ltd ピラノアジン誘導体
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
BR9809115A (pt) 1997-05-13 2002-01-02 Octamer Inc Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
AU740603B2 (en) 1997-06-02 2001-11-08 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
CN1159302C (zh) 1997-08-29 2004-07-28 武田舍林-普劳动物保健株式会社 三嗪衍生物,其制备及应用
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6340759B1 (en) 1997-10-02 2002-01-22 Eisai Co., Ltd. Fused pyridine derivatives
CA2307891A1 (fr) * 1997-10-28 1999-05-06 Byung-Hwa Hyun Emploi de la naringine et de la narigenine comme inhibiteurs de l'acyl coa-cholesterol-o-acyltransferase, et de l'accumulation de complexes macrophages/lipides sur la paroi arterielle, et comme agent de prevention et de traitement des troubles hepatiques
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
DE19756388A1 (de) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
ATE302267T1 (de) * 1998-01-08 2005-09-15 Aventis Pharma Inc Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
ES2299241T3 (es) 1998-03-17 2008-05-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para enfermedades intestinales inflamatorias que contienen anticuerpos antagonistas del receptor il-6.
US6022901A (en) * 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
JP2002526488A (ja) 1998-09-24 2002-08-20 三菱化学株式会社 ヒドロキシフラボン誘導体
KR20010103583A (ko) 1998-10-19 2001-11-23 다니구치 미즈오 진통제
WO2000023073A1 (fr) * 1998-10-20 2000-04-27 Korea Institute Of Science And Technology Flavonoides utilises comme agents augmentant la teneur en lipoproteines de haute densite du plasma
AU2190700A (en) 1998-12-17 2000-07-03 Tularik Inc. Tubulin-binding agents
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
KR20020008127A (ko) 1999-03-15 2002-01-29 스티븐 에프. 웨인스톡 항균 활성을 갖는 6-ｏ-치환된 매크롤라이드
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6054435A (en) * 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
PT1177187E (pt) 1999-04-28 2007-09-03 Sanofi Aventis Deutschland Derivados ácidos de di-arilo como ligados do receptor ppar.
US6835755B1 (en) 1999-06-24 2004-12-28 University Of Pretoria Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
JP2001131151A (ja) 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
JP5278983B2 (ja) 1999-11-17 2013-09-04 塩野義製薬株式会社 アミド化合物の新規用途
JP4880847B2 (ja) * 1999-12-06 2012-02-22 ウェリケム，バイオテック インコーポレーテッド ヒドロキシルスチルベンならびに新規スチルベン誘導体および類似体による抗炎症治療および乾癬治療ならびにプロテインキナーゼ阻害
FR2804679B1 (fr) 2000-02-07 2002-04-26 Clariant France Sa Nouveaux composes phenoliques derives des dialcoxyethanals, leur procede de preparation et leur application
WO2001060775A1 (fr) 2000-02-17 2001-08-23 Appleton Papers Inc. Procede de preparation d'aroxyethanes alcoxy ou arylmethoxy
WO2003018008A1 (fr) 2000-02-25 2003-03-06 Shionogi & Co., Ltd. Agent d'accélération de l'expression de apo ai
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
JP2001335476A (ja) 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
US6479499B1 (en) 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
JP2002047283A (ja) 2000-07-04 2002-02-12 Basf Ag 新規フラボノイドおよびそれらの化粧用または皮膚科用製品における使用
US6541522B2 (en) * 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CA2424300A1 (fr) 2000-10-02 2002-04-11 Molecular Probes, Inc. Reactifs pour le marquage de biomolecules a fractions aldehyde ou cetone
CA2356544C (fr) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines et pyridopyridazines
CZ20031230A3 (cs) * 2000-10-05 2003-10-15 Fujisawa Pharmaceutial Co., Ltd Benzamidový derivát a farmaceutický prostředek
EP1366024A2 (fr) * 2000-10-11 2003-12-03 Esperion Therapeutics Inc. Composes de sulfoxyde et de bis-sulfoxyde et compositions pour reguler le cholesterol, et applications associees
CA2425674A1 (fr) * 2000-10-11 2002-04-18 Jean-Louis H. Dasseux Composes et compositions de sulfure et de disulfure pour le traitement du cholesterol et utilisations associees
EP1333827A2 (fr) 2000-10-19 2003-08-13 Merck & Co., Inc. Modulateurs de recepteurs d'oestrogenes
KR100825182B1 (ko) * 2000-11-30 2008-04-24 캐논 가부시끼가이샤 발광 소자 및 표시 장치
IL156315A0 (en) * 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
KR100472694B1 (ko) * 2000-12-30 2005-03-07 한국생명공학연구원 플라바논 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
JP2002249483A (ja) 2001-02-21 2002-09-06 Koei Chem Co Ltd アリール置換複素環式化合物の製造法
JP4256679B2 (ja) 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法
AU2002320025A1 (en) 2001-04-11 2002-11-11 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
WO2003007959A1 (fr) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Derives de quinoxaline ayant une action inhibitrice sur parp
WO2003016292A1 (fr) 2001-08-13 2003-02-27 Ciba Specialty Chemicals Holding Inc. Absorbeurs de lumiere ultraviolette
US7429593B2 (en) * 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US8124625B2 (en) * 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
EP1426046A4 (fr) 2001-09-14 2005-11-02 Shionogi & Co Nouvelle utilisation de composes tricycliques
US6835469B2 (en) * 2001-10-17 2004-12-28 The University Of Southern California Phosphorescent compounds and devices comprising the same
US7166368B2 (en) 2001-11-07 2007-01-23 E. I. Du Pont De Nemours And Company Electroluminescent platinum compounds and devices made with such compounds
US7250512B2 (en) 2001-11-07 2007-07-31 E. I. Du Pont De Nemours And Company Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds
US6541045B1 (en) * 2002-01-04 2003-04-01 Nutraceutical Corporation Herbal composition and method for combating inflammation
EP1477481B1 (fr) 2002-01-28 2009-07-22 Ube Industries, Ltd. Procede de production de derive de quinazolin-4-one
US20040127492A1 (en) 2002-02-19 2004-07-01 Pharmacia Corporation Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
NZ556545A (en) 2002-03-22 2009-03-31 Novartis Ag Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003238157A1 (en) * 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
KR20040001144A (ko) * 2002-06-27 2004-01-07 김대경 신규한 적혈구 세포질형 포스포리파아제 에이 투 효소,그에 대한 항체, 이들의 용도 및 제조 방법
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20040033480A1 (en) * 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20040087590A1 (en) 2002-08-23 2004-05-06 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
US20040176366A1 (en) 2002-08-30 2004-09-09 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
EP1398032A1 (fr) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-oxoquinazolines se liant au récepteur nucléair LXR
EP1407774A1 (fr) * 2002-09-10 2004-04-14 LION Bioscience AG 2-amino-4-quinazolinones se liant au récepteur nucléair LXR
WO2004032846A2 (fr) 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Derives de la triazolone et de la triazolethione, inhibiteurs des metalloproteinases de matrices et/ou de l'enzyme de conversion du tnf$g(a)
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
WO2004039795A2 (fr) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Composes amide
CA2502302A1 (fr) 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Composes de quinazolinone utilises comme calcilytiques
EP1418164A1 (fr) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derivés de stilbène et leur utilisation en tant que antagonistes des ligands du recepteur des arylhydrocarbures
BR0316375A (pt) * 2002-11-18 2005-10-04 Hoffmann La Roche Diazinopirimidinas
CA2514473C (fr) 2002-11-22 2008-05-27 Japan Tobacco Inc. Heterocycles contenant de l'azote bicyclique fusionne
PL377474A1 (pl) * 2002-12-13 2006-02-06 F. Hoffmann-La Roche Ag Pochodne 3H-chinazolin-4-onu
ITRM20020629A1 (it) 2002-12-19 2004-06-20 Sigma Tau Ind Farmaceuti Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante.
DE60335911D1 (de) * 2002-12-20 2011-03-10 Daiichi Sankyo Co Ltd Isochinolinonderivate und deren verwendung als medikamente
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
EP1577288B1 (fr) * 2002-12-26 2014-07-23 Eisai R&D Management Co., Ltd. Modulateurs selectifs des recepteurs d'oestrogene
WO2004065392A1 (fr) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Pyridines et pyrimidines condensees et leur utilisation en tant que ligands du recepteur alk-5
WO2004072042A2 (fr) 2003-02-12 2004-08-26 Carex S.A. Modulation de l'activite de recepteurs nucleaires
CA2522595A1 (fr) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteines kinases
US7763627B2 (en) 2003-04-09 2010-07-27 Exelixis, Inc. Tie-2 modulators and methods of use
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
EP1629000B1 (fr) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Peptide d'isoquinoleine macrocyclique inhibiteurs du virus de l'hepatite c
ES2341545T3 (es) 2003-06-06 2010-06-22 Arexis Ab Uso de compuestos heterociclicos condensados como inhibidores de scce para el tratamiento de enfermedades de la piel.
EP1633718B1 (fr) 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. Compositions et procedes d'inhibition du facteur de croissance transformant beta (tgf-$g(b))
WO2004113307A1 (fr) 2003-06-18 2004-12-29 Ube Industries, Ltd. Procede de production d'un compose de pyrimidin-4-one
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
CA2541590A1 (fr) 2003-10-10 2005-04-21 Resverlogix Corp. Traitement de maladies associees a la sequence activatrice egr-1
US20050096391A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
CA2540460A1 (fr) 2003-10-28 2005-05-12 Reddy Us Therapeutics, Inc. Composes heterocycliques, leurs procedes de fabrication et leur utilisation
EP1696927A4 (fr) 2003-12-19 2007-10-31 Merck & Co Inc Inhibiteurs mitotiques de la kinesine
WO2005066162A1 (fr) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Composes synthetiques et derives de ceux-ci en tant que modulateurs de fumee ou d'ingestion de nicotine et du cancer du poumon
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
JPWO2005115993A1 (ja) * 2004-05-31 2008-03-27 萬有製薬株式会社 キナゾリン誘導体
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006012577A2 (fr) 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments
US20070218155A1 (en) * 2004-08-20 2007-09-20 Kuhrts Eric H Methods and compositions for treating dyslipidaemia
CA2584485C (fr) * 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes et chalcones utilises pour la prevention et le traitement de maladies cardio-vasculaires
WO2006071095A1 (fr) 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CN101365446B (zh) * 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
CA2627139A1 (fr) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Nouveau derive de benzoxathiine
CA2634491A1 (fr) 2005-12-21 2007-06-28 Painceptor Pharma Corporation Compositions et procedes de modulation de canaux ioniques commandes par porte
EP1928425B1 (fr) 2006-05-12 2013-01-23 Pharmathen S.A. Formulation pharmaceutique contenant du fluvastatin
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
WO2008059024A1 (fr) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc 2-(2-hydroxyphényl)-quinazolin-4-ones utilisées pour traiter l'obésité et le diabète
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
MX2009008099A (es) * 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
ES2308916B1 (es) 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
EP2005941A3 (fr) 2007-06-01 2009-04-01 Henkel AG & Co. KGaA Compositions rajeunissant les cellules
WO2008152471A1 (fr) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Antagoniste des récepteurs de type toll et ses utilisations
MX2009013781A (es) 2007-06-21 2010-02-01 Irm Llc Inhibidores de cinasa de proteina y metodos para el uso de los mismos.
JP5478262B2 (ja) 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
CA2732087A1 (fr) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Naphtyridines substituees et leur utilisation en tant que medicaments
EA201100609A1 (ru) 2008-10-06 2011-12-30 Каролус Терапьютикс, Инк. Способы лечения воспаления
US8569288B2 (en) 2008-10-30 2013-10-29 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
US20100183598A1 (en) 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
TW201035083A (en) 2009-03-06 2010-10-01 Hoffmann La Roche Heterocyclic antiviral compounds
CA3146333A1 (fr) 2009-03-18 2010-09-23 Resverlogix Corp. Derives de la phenyl-quinazolin-4(3h)-one et de la phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one et leurs compositions utiles comme agents anti-inflammatoires
PL2421533T3 (pl) 2009-04-22 2019-05-31 Resverlogix Corp Nowe środki przeciwzapalne
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2353093B1 (es) 2009-05-20 2012-01-03 Consejo Superior De Investigaciones Científicas (Csic) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2827585A1 (fr) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statine et acides gras omega-3 (epa, dha et dpa) utilises dans les maladies cardiovasculaires
WO2012174487A2 (fr) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
WO2013049352A2 (fr) 2011-09-30 2013-04-04 Kineta, Inc. Composés anti-viraux
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2864336B1 (fr) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromo-domaine de benzo[b]isoxazoloazépines et applications associées
AU2013333575B2 (en) 2012-10-15 2015-07-16 Resverlogix Corp. Compounds useful in the synthesis of benzamide compounds
BR112015008171B1 (pt) 2012-10-15 2021-01-19 Albemarle Corporation processos para a síntese de 2-amino-4,6-dimetoxibenzamida e de outros compostos de benzamida
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
WO2014110090A1 (fr) 2013-01-08 2014-07-17 Jerome Schentag Activation de la voie de l'hormone endogène du frein iléal pour la régénérescence d'un organe et des compositions associées, méthodes de traitement, diagnostics, et systèmes de régulation
CA2902225A1 (fr) 2013-02-28 2014-09-04 Washington University Methodes de traitement de maladies et d'infections par le cytomegalovirus humain au moyen d'inhibiteurs de bromodomaines
JP6401773B2 (ja) 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
CA2905451A1 (fr) 2013-03-14 2014-10-02 Convergene Llc Procedes et compositions pour l'inhibition de proteines contenant un bromodomaine
MX370538B (es) 2013-03-27 2019-12-17 Hoffmann La Roche Marcadores genéticos para la predicción de respuesta a la terápia.
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
MX2016002302A (es) 2013-08-21 2016-06-15 Resverlogix Corp Composiciones y metodos terapeuticos para la regresion acelerada de placa.
US20160346291A1 (en) 2013-08-21 2016-12-01 Resverlogix Corp Compositions and therapeutic methods for accelerated plaque regression
US9814728B2 (en) 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
EP3097088A4 (fr) 2014-01-23 2017-10-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dérivés de l'icariine
PT3174995T (pt) 2014-07-30 2020-10-15 Hoffmann La Roche Marcadores genéticos para prever o tipo de resposta ao tratamento com um fármaco de aumento do hdl ou mimetizador do hdl
WO2016123054A2 (fr) 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Combinaisons de médicaments à base de kinase et leurs procédés d'utilisation
WO2016145294A1 (fr) 2015-03-12 2016-09-15 The University Of Chicago Procédés pour déterminer un pronostic pour des patients atteints de cancer du sein
EP3268007B1 (fr) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
WO2016182904A1 (fr) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Sélection ciblée de patients pour un traitement par dérivés de cortistatine
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN106265679A (zh) 2015-06-28 2017-01-04 复旦大学 溴结构域蛋白抑制剂在制备抗hiv-1潜伏治疗药物中的用途
US20180200261A1 (en) 2015-07-20 2018-07-19 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
US9896663B2 (en) 2016-03-11 2018-02-20 Peter Maccallum Cancer Institute Leukaemia stem cell line, its method of production and uses thereof
WO2017192691A1 (fr) 2016-05-03 2017-11-09 Biogen Ma Inc. Culture cellulaire contenant des inhibiteurs de bromodomaine
CN106176753A (zh) 2016-07-15 2016-12-07 南方医科大学 Rvx‑208作为hiv‑1潜伏感染逆转剂的应用
JP6849804B2 (ja) 2016-12-09 2021-03-31 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途

Also Published As

Publication number Publication date
JP2010517946A (ja) 2010-05-27
US20080188467A1 (en) 2008-08-07
US20150072955A1 (en) 2015-03-12
US20120015905A1 (en) 2012-01-19
SI2118074T1 (sl) 2014-05-30
WO2008092231A1 (fr) 2008-08-07
AU2007345526B2 (en) 2013-02-28
US8053440B2 (en) 2011-11-08
CA2676984A1 (fr) 2008-08-07
KR20100014845A (ko) 2010-02-11
EP2118074B1 (fr) 2014-01-22
CN101641339B (zh) 2013-07-17
CA2676984C (fr) 2015-03-17
EP2118074A1 (fr) 2009-11-18
US20200352946A1 (en) 2020-11-12
US20210361656A1 (en) 2021-11-25
ES2454966T3 (es) 2014-04-14
KR101444489B1 (ko) 2014-09-24
CN101641339A (zh) 2010-02-03
NZ579355A (en) 2012-03-30
US20160106750A1 (en) 2016-04-21
EP2118074A4 (fr) 2011-06-15
PL2118074T3 (pl) 2014-06-30
US10532054B2 (en) 2020-01-14
US9199990B2 (en) 2015-12-01
AU2007345526A1 (en) 2008-08-07
DK2118074T3 (en) 2014-03-10
PT2118074E (pt) 2014-03-20
MX2009008099A (es) 2009-12-14
AU2007345526A2 (en) 2009-10-08
US8889698B2 (en) 2014-11-18
US20180104245A1 (en) 2018-04-19
JP5236664B2 (ja) 2013-07-17
CY1115236T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
WO2010079431A3 (fr) Composés pour la prévention et le traitement de maladies cardiovasculaires
WO2013064900A8 (fr) Compositions pharmaceutiques pour des quinazolinones substituées
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
WO2013153479A3 (fr) Composés d'indole et d'indazole qui activent l'ampk
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
HK1138572A1 (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2009151598A8 (fr) Diazacarbazoles et procédés d’utilisation
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
WO2010014253A3 (fr) Composés inhibiteurs d’ant4 et leurs procédés d’utilisation
MX2010010877A (es) Compuestos y composiciones como inhibidores de itpkb.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.